GSK‐29060/525.

Methods	Study design: Randomised controlled trial
Participants	Diagnosis: Panic disorder; no further details provided Method of diagnosis: Not stated Age: for paroxetine, M = 37.12 (SD = 9.92); for clomipramine, M = 40.13 (SD = 11.34) Sex: for paroxetine, 14 women, 23 men, 1 unknown; for clomipramine 17 women, 14 men Location: China; setting unclear Co‐morbidities: patients with current major depression were excluded. No other co‐morbidities mentioned Rescue medication: Not stated
Interventions	Participants were randomly assigned to either: (1) paroxetine arm (n = 38) Duration: 10 weeks Treatment Protocol: flexible dosage; range = 10 ‐ 50 mg, M and SD not provided (2) clomipramine arm (n = 35) Duration: 10 weeks Treatment Protocol: flexible dosage; range = 50 ‐ 100 mg, M and SD not provided
Outcomes	Time points for assessment: baseline, endpoint (10 weeks) Outcomes: 1. mean change from baseline in the number of full panic attacks 2. Hamilton Rating Scale for Anxiety (HAMA) 3. Panic Associated Symptoms Scale 4. Clinical Global Impression Severity of Illness Score (CGI‐S) 5. Patient Global Evaluation (PGE)
Notes	Date of study: September 1998 to September 1999 Funding source: GSK Declarations of interest among the primary researchers: Not stated.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Quote: "randomized".
Allocation concealment (selection bias)	Unclear risk	No information provided.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double‐blind". No further details.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Quote: "double‐blind". No further details.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Quote: "ITT population consisted of all subjects who received treatment and have one post treatment evaluation".
Selective reporting (reporting bias)	Low risk	All outcomes were reported.
Other bias	High risk	Sponsored by GSK; the role of the funder in planning, conducting and writing the study is not discussed.